Abbreviations
tumor, Necrosis, Tumor
TUMOR, TUMOR, POSITIVE, DISEASE, SOLID TUMORS, NECROSIS, TRANSFORMING, ADVERSE EVENT, CPS
HPV, human papillomavirus; WoS, Web of Science; ICTRP, International Clinical Trials Registry Platform; FDA, Food and Drug Administration; TS, topic subject; RECIST, response evaluation criteria in solid tumors; ORR, overall response rate; DCR, disease control rate; mDoR, median duration of response; mOS, median overall survival; mPFS, median progression free survival; DFS, disease free survival; HR, hazard ratio; TRAE, treatment-related adverse event; TEAE, treatment-emergent adverse event; TMB, tumor mutational burden; ACT, adoptive cell therapy; CTLA, cytolytic T lymphocyte-associated Antigen; TIGIT, T cell immunoglobulin and ITIM domain; ICOS, inducible T-cell co-stimulatory; GITR, Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TIL, tumor-infiltrating lymphocyte; CIK, cytokine-induced killer cell; LAK, lymphokine-activated killer cell; ADC, antibody-drug conjugates; TF, tissue factor; TGF, Transforming Growth Factor; TKI, tyrosine kinase inhibitor; ICB, immune checkpoint blockade; BA, bispecific antibody; TME, tumor microenvironment; TCR-T, T-Cell Receptor T Cell; CAR-T, Chimeric Antigen Receptor T Cell; CPS, Combined Positive Score; CCRT, Concurrent Chemoradio Therapy; MHC, Major Histocompatibility Complex; TNF, Tumor Necrosis Factor; IFN, Interferon; AUC, Area Under Curve; q3w, 3 weeks using a; NR, not reached.